Dec 4, 2008 by Brian Orelli, PhDDrug Deals Require CashPharmaceutical companies find out how nice it is not to have to take out loans.
Dec 4, 2008 by Brian Orelli, PhDPfizer Blows Statin SmokeIt presents some mildly persuasive numbers to try to win back customers for Lipitor.
Dec 3, 2008 by Brian Orelli, PhDHigh-Margin Generic Drugmakers -- An Oxymoron?Not if patent suits go their way.
Dec 2, 2008 by Brian Orelli, PhDCongratulations, It's a WebsiteUnitedHealth jumps on the health website bandwagon.
Dec 1, 2008 by Brian Orelli, PhDJohnson & Johnson Firms Things UpThe health-care giant acquires breast-implant maker Mentor.
Dec 1, 2008 by Brian Orelli, PhDObama Can't Save Stem Cell CompaniesBut there are a few companies that can.
Dec 1, 2008 by Brian Orelli, PhDIt's Wait Until Next Year for These DrugmakersDrugs from AstraZeneca and Eli Lilly face delays because of the FDA.
Dec 1, 2008 by Brian Orelli, PhDHealth Insurers' Universal UncertaintyUniversal health care is putting a damper on insurers.
Nov 28, 2008 by Brian Orelli, PhDThe FDA's Killing Bug KillersThe agency turns down another antibiotic.
Nov 28, 2008 by Brian Orelli, PhDBargain Stocks for Black Friday: Intuitive SurgicalSurgical robots on the cheap.
Nov 28, 2008 by Brian Orelli, PhDWill Patients Reject This Injection?Wyeth and Progenics release good trial data, but will patients want their constipation drug?
Nov 26, 2008 by Brian Orelli, PhDTeva and AstraZeneca's Drama ConcludesBut investors are still left in the dark.
Nov 25, 2008 by Brian Orelli, PhDGenentech ExhalesThe biotech had everything to lose and almost nothing to gain with its recent clinical trial.
Nov 25, 2008 by Brian Orelli, PhDExelixis Has Friends With CashBristol-Myers picks up one of the drugs from its collaboration.
Nov 25, 2008 by Brian Orelli, PhDSchering's Peacock ImitationThe company lays out its pipeline for investors to digest.
Nov 24, 2008 by Brian Orelli, PhDIs Amgen's Nplate a Blockbuster?Amgen gets a positive recommendation from European officials.
Nov 24, 2008 by Brian Orelli, PhDBristol Rolls Snake Eyes in EuropeEuropean officials reject its breast cancer treatment, Ixempra.
